Viral factors affecting the outcome of therapy for chronic hepatits C

Reviews in Gastroenterological Disorders

Volumn 4, Issue SUPPL. 1, 2004, Pages

  Fried, Michael W ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Dynamic change in HCV RNA; Early virologic response; Genotype; Hepatitis C; Sustained virologic response

Indexed keywords

INTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PLACEBO; PROTEINASE INHIBITOR; RIBAVIRIN; VIRUS RNA; ALPHA2A INTERFERON; MACROGOL DERIVATIVE; PEGINTERFERON ALFA-2A;

ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; DRUG RESPONSE; DRUG WITHDRAWAL; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; INDIVIDUALIZATION; MEDICAL DECISION MAKING; PREDICTION; QUANTITATIVE ANALYSIS; RNA ANALYSIS; SENSITIVITY ANALYSIS; TREATMENT FAILURE; TREATMENT OUTCOME; COMPARATIVE STUDY; DRUG COMBINATION; DRUG EFFECT; FEMALE; GENETICS; HOSPITALIZATION; MALE; PHARMACOGENETICS; REVIEW; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; VIRUS LOAD;

DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; MALE; PHARMACOGENETICS; POLYETHYLENE GLYCOLS; RIBAVIRIN; RISK ASSESSMENT; RNA, VIRAL; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VIRAL LOAD;

EID: 2942696419     PISSN: 1533001X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Pawlotsky JM. Hepatitis C virus genetic variability: pathogenic and clinical implications. Clin Liver Dis. 2003;7:45-66.
2. Forns X, Bukh J. The molecular biology of hepatitis C virus: genotypes and quasispecies. Clin Liver Dis. 1999;3:693-716, vii.
3. Moradpour D, Brass V, Gosert R, et al. Hepatitis C: molecular virology and antiviral targets. Trends Mol Med. 2002;8:476-482.
4. Pawlotsky JM, McHutchison JG. Hepatitis C. Development of new drugs and clinical trials: promises and pitfalls. Hepatology. 2004; 39:554-567.
5. Lamarre D, Anderson PC, Bailey M, et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature. 2003;426:186-189.
6. Fried MW, Shiffman ML, Reddy KR, et al. Combination of peginterferon alfa-2a plus ribavirin in patients with chronic hepatitis C virus infection. N Engl J Med. 2002;347:975-982.
7. Fried MW, Peter J, Hoots K, et al. Hepatitis C in adults and adolescents with hemophilia: a randomized, controlled trial of interferon alfa-2b and ribavirin. Hepatology. 2002;36:967-972.
8. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958-965.
9. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140:346-355.
10. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C 2002 (June 10-12, 2002). Gastroenterology. 2002;123:2082-2099.
11. Russo MW, Zacks SL, Fried MW. Management of newly diagnosed hepatitis C virus infection. Cleve Clin J Med. 2003;70(suppl 4):S14-S20.
12. Davis GL, Wong JB, McHutchison JG, et al. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology. 2003; 38:645-652.
13. Russo MW, Fried MW. Hepatitis C therapy: guidelines for stopping therapy. Curr Gastroenterol Rep. 2004;6:17-21.
14. Davis GL. Monitoring of viral levels during therapy of hepatitis C. Hepatology. 2002;36:S145-S151.
15. Pawlotsky JM, Bouvier-Alias M, Hezode C, et al. Standardization of hepatitis C virus RNA quantification. Hepatology. 2000;32:654-659.
16. Pawlotsky JM. Use and interpretation of virological tests for hepatitis C. Hepatology. 2002;36:S65-S73.
17. Berg T, Sarrazin C, Herrmann E, et al. Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. Hepatology. 2003;37:600-609.